Regional Chemotherapy and Brachytherapy for Malignant Glioma – Clinical Experience and Serial Experiments by Li Anmin et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
10 
Regional Chemotherapy and Brachytherapy for 
Malignant Glioma – Clinical Experience  
and a Serial Experiments 
Li Anmin, Fu Xiangping, Zhao Ming, Zhang Zhiwen,  
Yi Linhua, Xue Jinghui and Zhang Yipeng 
Department of Neurosurgery, First Affiliated Hospital of Chinese PLA General Hospital, 
China 
1. Introduction 
Malignant glioma (MG) is the most common type of malignant tumors derived from 
neuroepithelial tissue, and accounts for 46% of brain tumors. It has an incidence of 30-
100/million and ranks third in adult mortality and second in child mortality in all cancer 
patients. Compared with malignant tumors from other tissues and organs,  MG has much 
lower treatment success rates. Despite global efforts over the past thirty years, there has 
been no major breakthrough in treatment and patient survival has not significantly 
improved. The median survival time after diagnosis is eight months in patients receiving 
surgery alone and 11 months in patients receiving surgery plus adjuvant 
radiotherapy/chemotherapy. Conventional treatments for MG include surgical resection, 
adjuvant whole brain radiotherapy (WBRT), and systemic chemotherapy. Limitations of 
these treatments include:  
1. Surgical resection: MG is highly invasive. As a result, total resection is typically  
not achieved in surgery. The operation may also activate residual tumor cells  
from the G0 phase to the proliferation phase, resulting in tumor recurrence of 
malignancy.   
2. Post-operative WBRT. The effective dose for MG (73-80 Gy) is higher than the 
maximum tolerated dose for brain tissue (60 Gy). The therapeutic effects at a dose of 60 
Gy are mediated primarily by radioactive ions that stimulate endotheliocytosis in the 
microvascular bed of the tumor. The endotheliocytosis results in embolism and 
decreased blood supply to tumor. 
3. Post-operative chemotherapy. Upon systemic treatment, only ~20% of 
chemotherapeutic agents reach the brain. The blood brain barrier (BBB) around the 
post-operative tumor cavity also prevents the chemotherapeutic agents from reaching 
the site of action. 
The weak immunogenicity of the glioma membrane and the heterogeneity of the cells have 
limited the application of immunotherapy. The unique biological properties and lack of 
effective clinical treatment creates a challenge for clinical practice and basic experimental 
research [1,2]. 
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The growth of MG tends to be localized. Such a feature may represent an opportunity to 
develop novel treatment for MG [3]. Specifically, we propose that localized tumor should be 
treated with regional therapy. 
Over 18 years of clinical research (Apr 1991 to Dec 2008), the authors developed new 
regional treatments. These new treatments incorporated three therapeutic concepts: 
emphasizing the “first strike” to the tumor, maintaining a high quality of life for the 
patients, and devising individual treatment plans for patients. 
Clinical research provided satisfactory and promising outcomes for regional therapy. In 
addition, in vivo and in vitro experimental results showed that the implementation of 
regional treatment methods could control residual tumor growth and invasive behaviors. 
Data accumulated with 10-year follow-up in 379 patients confirmed that the new regional 
treatments improved the survival as well as the quality of life in patients with MG.  
2. New regional therapies for MG 
The authors introduced the idea that localized tumors should be treated with regional 
therapy and developed seven new methods for such regional therapy. With these new 
methods, we achieved 16.6% 3-year survival rate in MG patients. Strikingly, the tumor 
disappeared in 6.3% of the cases. The seven new methods can be classified as regional 
chemotherapy or brachytherapy. 
i. Regional chemotherapy 
1. Intra-tumoral interstitial chemotherapy 
2. Selective/super-selective interventional chemotherapy via the cerebral artery  
3. High-dose chemotherapy supported by autologous stem cells 
ii. Brachytherapy 
1. Intra-tumoral brachytherapy 
2. Immunologically targeted radiotherapy via 131I labeled McAb 
3. Tumor interstitial brachytherapy 
4. Brachytherapy for MG located in the brain stem or spinal cord  
3. Intra-tumoral interstitial chemotherapy 
Regional chemotherapy was explored for decades in the world [4-7]. In 1991, the authors used 
a patented chemotherapy reservoir (Li Anmin I reservoir, Fig.1-A) for postoperative intra-
tumor interstitial chemotherapy. From Jan 2001 to Dec 2008, 151 of 379 patients received this 
chemotherapy. 
3.1 Methods 
After MG resection, the chemotherapy reservoir was implanted into the residual tumor 
cavity (Fig.1-B). Chemotherapeutic agents were injected into the extracranial capsule and 
then into the residual tumor cavity via the reservoir tube. The chemotherapeutic agents 
used for this treatment (BCNU, VM, and ACNU) have low molecular weight, and could 
permeate the residual tumor cavity wall and tumor cell membrane. Doses for these agents 
were 25 mg for BCNU, 50 mg for VM26, and 25-50 mg for ACNU. The injection began at 7 
d after the operation and continued daily for 4 d. When tumor growth was under control 
(Fig. 2), the interval between the injections was increased to 30-40 d. The entire treatment 
lasted for 2 yr. 
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Fig. 1-A. Photo of Chemotherapeutic Reservoir  㸦Li Anmin Type I Reservoir㸧 
 
 
Fig. 1-B. The sketch of interstitially intratumoral chemotherapy postoperatively:  
1. Residual tumor cavity, 2. Valve of the reservoir, 3. Tube of the reservoir 
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Fig. 2. The sketch of interstitially intratumoral chemotherapy 
3.2 Side effects  
There was no general toxicity during or after drug injection. Headache (typically tolerable 
was observed in some patients receiving VM26 or BCNU. Seizure developed in 2.7% of 
the patients receiving VM26 or BCNU. ACNU did not cause discomfort in any patient 
(Table 1). 
The Li Anmin I reservoir has several advantages over Ommaya reservoir. First, the 
extracranial capsule of the new reservoir has a steel or titanium basement plate, which 
prevents it from being pierced during the drug injection. Second, the tube of the new 
reservoir extends from the side of the external capsule rather than from the bottom as in the 
Ommaya reservoir[8,9]. This new configuration facilitates fixation and reduces the capsule 
volume. 
Overall, hawse has achieved positive therapeutic outcomes with tolerable adverse effects 
with this method. As a result, it is now widely adopted in China. 
 
 BCNU VM26 ACNU 
Inhibitive efficiency ++ + +++ 
Effective radius cm >3 cm <3 cm 
Necrosis feature 
Coagulation 
necrosis 
Liquefaction 
necrosis 
Coagulation 
necrosis 
Local effect ++ +++ ++ 
Toxicity ++ +++ + 
Table 1. Three chemotherapeutic agents used in intra-tumoral interstitial chemotherapy. 
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4. Selective/super-selective interventional chemotherapy via the cerebral 
artery 
In early 1990s in China, interventional therapy via the cerebral artery was primarily a tool 
for the diagnosis and treatment of cerebrovascular diseases. In 1993, the authors presented 
the first use of interventional chemotherapy via cerebral artery for the treatment of MG.0 
4.1 Methods 
There are three major methods currently used by the authors in the cerebral 
interventional chemotherapy (Fig. 3): intervention by common carotid artery, 
intervention by femoral-internal carotid (supraclinoid)/vertebrobasilar artery (selective 
chemotherapy), and intervention by femoral-tumor feeding artery (super-selective 
chemotherapy).  
 
 
Fig. 3. The sketch of interventional chemotherapy via cerebral artery 
4.2 Side effects 
From Apr 1991 to Dec 2008, 677 patients received this therapy, and 4916 operations were 
performed. The side effects for interventional chemotherapy included three cases of vision 
reduction, perhaps due to embolism of retinal arteriole by chemotherapeutic micro-
lipoparticles, one case of hemiplegia caused by breaking off of the plaque in the bifurcation 
and embolized of ICA during the punctuation of CCA. Leucopenia and thrombocytopenia 
developed in 92 cases (24.4%), but recovered within four weeks of withdrawal in most cases. 
In seven cases, white blood cell count was too low to continue the chemotherapy. 
Spontaneous hemorrhagic tendency (the thrombocytopenia after chemotherapy had no 
effective treatment to promote the recovery of bone marrow function) occurred in two cases. 
Myelofibrosis was observed in one case. 
Cerebral artery interventional chemotherapy significantly reduced the adverse effects of 
chemotherapeutic agents and elevated the intratumoral local drug concentration by more 
than 15-fold (Fig. 4). From 2001 to 2008, 283 of 379 cases were treated with interventional 
chemotherapy, and 158 cases (56.0%) had favorable outcomes. This method has been 
adopted widely (Fig. 5). 
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Typical case: 
 
    
MRI after first surgery 
MRI after second 
surgery
MRI  of glioma
recurrence
CT after 8-month 
chemotherapy  
Fig. 5. The male patient was 30 years old with recurrent glioblastoma multiform, treated 
with interventional chemotherapy 
5. High dose chemotherapy supported by Autologous Peripheral Blood Bone 
Marrow Stem Cell (APBBMSC) 
Based on the dose-effect curve of chemotherapeutic agents, the authors used high-dose 
chemotherapy (twice the normal dose) to treat MG. In 2003, we introduced APBBMSC-
supported high-dose chemotherapy for MG. Beginning at five days before chemotherapy, 
300 µg of granulocyte colony stimulating factor (G-CSF) was injected daily to stimulate 
APBBMSCs. The APBBMSCs were isolated from peripheral blood and concentrated in a 60 
mL suspension. The cell concentration was adjusted to 1.0 × 109 cells/mL with Tc-199 cell 
culture solution blended with buffer solution (60% Tc-199, 20% dimethyl sulfoxide, 20% 
autologous plasma). APBBMSC was stored in liquid nitrogen. After the high-dose 
chemotherapy, frozen APBBMSCs were thawed rapidly at 4ºC and administered 
intravenously at 48-72 h post-chemotherapy (Fig. 6). 
 
 
Fig. 6. The procedure of chemotherapy supported by autotransplantation of peripheral 
blood bone marrow stem cells.  
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Following this treatment, the WBC count decreased for 3-7 d, reaching the lowest values at 
5-10 d, and increased to >1.0 × 109 cells/L in 6-10 d. The PLT levels typically returned to 
>50.0 × 109/L in 12-15 d. In the 74 patients receiving only conventional chemotherapy, WBC 
count reduced to <1.0 × 109/L and PLT levels reduced to <20.0 × 109/L. The low levels 
remained for 16-31 days before returning to normal. 
In this series, the overall effective rate was 55.6% (total number of patients: 27; 2 CR cases, 13 
PR cases, 10 MR cases, 1 NC case, and 1 PD case; Fig. 7). 
Typical case: 
 
  
MRI before treatment MRI after 21-month treatment 
Fig. 7. The male patient was 49 years old with recurrent GBM, treated with chemotherapy 
supported by autotransplantation of peripheral blood bone marrow stem cells, 
superselectively intervetional chemotherapy and targeted immunoradiotherapy with 
monoclonal antibody labelled 131I. 
This study indicated that APBBMSC-supported high-dose chemotherapy offers the 
advantage of rapid recovery of bone marrow after high-dose chemotherapy. Compared with 
bone marrow transplants following chemotherapy, APBBMSC-supported high-dose 
chemotherapy is easy to perform and could achieve rapid recovery of hematopoietic 
function with limited side effects [10]. 
6. Intra-tumoral brachytherapy 
In 1993, the authors developed a radiotherapy reservoir (Li Anmin II reservoir, Fig. 8-A) to 
perform postoperative intra-tumoral brachytherapy for MG. This treatment was used in 172 
of the 379 patients.  
6.1 Methods 
After surgical removal of the tumor, a brachytherapy reservoir was implanted into the 
residual tumor cavity, and the valve of the reservoir was embedded subcutaneously (Fig. 8-
B). Radioactive isotopes (125I or 131I) were injected through the reservoir valve into the 
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reservoir. The reservoir formed an oval-shaped radioactive envelope (Fig. 9), and produced 
localized, long-term, high-dosage irradiation to the residual cavity and the surrounding 
region for two half lives (125I t1/2=120 days and 131I t1/2=16 days).  
 
 
Fig. 8-A. Photo of Radiotherapeutic Reservoir (LiAnmin Type II reservoir) 
 
 
Fig. 8-B. The sketch of intratumoral brachytherapy: 1.Residual tumor cavity,  
2. Valve of the reservoir, 3. Sack of the reservoir 
 
                           
MRI before treatment The sketch of treatment 
CT after 9-month 
treatment
Fig. 9. The sketch of intratumoral brachytherapy 
www.intechopen.com
Regional Chemotherapy and Brachytherapy  
for Malignant Glioma – Clinical Experience and a Serial Experiments 
 
247 
The isotopes emited high-energetic particles to damage the ultra micro-structure of DNA in 
MG cells. Simultaneously, hyperplasia of vascular endotheliocytes was induced, reducing 
blood supply to the tumor.  
According to the radiometric determination from the water and wax model, brachytherapy 
produced a 3- to 5-fold larger absorption than routine extracranial irradiation of 10-20 
cGy/h. These results are in accordance with Gutin’s report. To measure the radioactivity 
absorbed in the remnant tumor, we used an radioactivity detector (NE Company UK Ionex 
2500/3) and a finger-shaped ionization chamber. Calculation using the formula Or = 51.2 ×C 
×(niEi ψI)cGy/d resulted in 30.4-91.3 cGy/h or 730-3190 cGy/d absorption by remnant 
tumor. 
The extent of brain edema in normal brain tissue was lower than that after routine 
radiotherapy. Light and electron microscopy of brain tissue samples from a patient 
treated by intra-tumoral brachytherapy revealed that there was no tumor growth within 3 
cm of the implanted radioactive source and that tumor cells 4 cm from the source were 
inactive. 
This treatment offers several advantages over routine radiotherapy. First, the isotope was 
much closer to the residual tumor cells (Fig. 10). As a result, efficacy was improved; 
toxicity was reduced. Second, the isotope was sealed within the reservoir without leakage 
into the body. Third, survival time and quality of life improved in this treatment 
compared to the control group. The survival time increased with increasing radioactive 
dose. Finally, according to tumor proliferation during treatment, when patients need 
additional treatment, the reservoir can be refilled with the radioactive isotope through the 
subcutaneous valve. 
Typical case: 
 
  
Postoperative CT scan before treatment 
CT after 2-year treatment. The patient is still 
alive. 
Fig. 10. The male patient was 57 years old with recurrent glioblastoma multiform, treated 
with intra-tumoral brachytherapy and intratumorally interstitial chemotherapy. 
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7. Intratumoral interstitial brachytherapy 
Beginning in 2002, the authors performed interstitial brachytherapy in patients with tumors 
in central or functionally important locations. The Li Anmin I reservoir was implanted 
stereotactically (Fig. 11-A). 1.5 mL of 30 mCi 131I solution was injected into the tumor site 
postoperatively at a constant speed (0.25 mL/h). Tumor cells were eliminated by short-
distance radiation during the regeneration of interstitial fluid (Figs. 11-B and 12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 11-A. The sketch of procedure of Intratumoral interstitial brachytherapy 
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Fig. 11-B. CT and ECT at 24h, 8d, 16d and 30d after intratumoral interstitial brachytherapy. 
 
 
Fig. 12. The sketch of three structure levels of intratumoral interstitial brachytherapy for 
brain tumor. 
This therapy involves three primary mechanisms (Fig. 13). First, a high-energy liquid 
radioactive source was placed at the interface of tumor and normal brain tissues, preventing 
the tumor from invading deep structures. Second, the liquid isotope flowed out of the 
reservoir into the interstitial fluid, irradiating tumor cells during the regeneration of the 
interstitial fluid. Finally, the liquid radioactive agents within the reservoir tube formed a 
radioactive column inside the tumor, subjecting it to continuous radiation for >16 d (2 half 
lives of 131I). The 131I fluid can be refilled to prolong the radioactive exposure. 
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Fig. 13. The sketch of intratumoral interstitial brachytherapy 
Based on long-term follow-up from Jan 2006 to Jul 2008, 33 patients who received the 
therapy had a prolonged survival time and a significantly improved quality of life (Fig. 14). 
Typical case: 
 
   
MRI of Recurrent glioma  
LiAnmin I reservoir was implanted 
stereotactically. 
Postoprational CT showed the position of 
intratumoral tube.
 
 
2.5 years after intratumoral interstitial brachytherapy 
Fig. 14. Female，42 years old，recurrent anaplastic astrocytoma 
Treatment: 
1. Intratumoral interstitial brachytherapy. 
2. Selective/superselective interventional chemotherapy via cerebral artery 
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7.1 Complications and prevention 
Hypothyroidism is a common complication in patients receiving long-term, cumulative 
exposure to micro-doses of 131I, but could be prevented by iodine treatment prior to and 
during the exposure.  
8. Immunologically targeted radiotherapy via monoclonal antibodies (McAb) 
loaded with 131I 
Immunologically targeted radiotherapy was designed for targeted brachytherapy [11]. Due to 
the weak immunogenicity and heterogeneity of glioma cells, an anti-nucleus McAb loaded 
with 131I works better than an anti-membrane antibody. The chimeric McAb binds 
specifically to histones inside the dying tumor cells to destroy the adjacent tumor cells with 
high-dose local irradiation (Fig. 15).  
 
 
Fig. 15. Sketch of Comparison between Immunologically Targeted Radiotherapy via anti-
membrane and anti-nucleus McAb loaded 131I in glioma  
In collaboration with Epstein at the Department of Pathology, University of Southern 
California, the authors completed a phase II clinical trial in 56 MG patients in China. Of the 
56 patients, 37.5% showed marked improvement and 42.8% showed mild improvement. The 
1-year survival rate was 92.8%. 
The recommended intrathecal administration resulted in accumulation of radioactive isotopes 
in the subarachnoid space and cerebral cistern rather than in the tumor tissue (Fig. 16). 
Additionally, intrathecal administration induced adverse effects on thyroid and bone marrow. 
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By contrast, when drugs were administered to the tumor via the Li Anmin I reservoir, the 
adverse effects on the thyroid and bone marrow were reduced (Fig. 17). 
 
 
Fig. 16. ECT images of 2 methods of treatment 
In May 2004, the China Cooperation Team Conference of Immune Targeted Radiotherapy 
was held in Shanghai. The authors proposed the local administration with LiAnmin I 
reservoir, which got extensive affirmation and widely accepted as the general method of 
immune targeted radiotherapy for MG in China. 
Typical case:  
 
  
Before treatment 7 years after treatment 
Fig. 17. Male，62 years old，GBM 
Treatment: 
1. Immunologically targeted radiotherapy via McAb loaded 131I 
2. Selective interventional chemotherapy via cerebral artery 
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Following positive reception at the China Cooperation Team Conference of Immune 
Targeted Radiotherapy (Shanghai, May 2004), local administration of anti-nucleus McAb 
loaded with 131I via the Li Anmin I reservoir gained wide acceptance, and has become the 
golden standard of immune targeted radiotherapy for MG in China. 
9. Peritumoral brachytherapy for MG in the brain stem/spinal cord 
MG accounts for 59% of tumors in the brain stem and approximately 15% of the tumors in 
the spinal cord. Their survival rate is not correlated to the extent of surgical resection, but to 
the aggressiveness and postoperative proliferation of the residual tumor. Because of the 
infiltrative growth of the tumor, surgical resection has the risk of damaging the brain stem 
and spinal cord and threatening the quality of life. Conventional radiotherapy only inhibits 
tumor growth for ~3 months and does not affect the recurrent tumor.  
Between Sept 2005 and Dec 2008, 15 patients were treated with peritumoral brachytherapy. 
In a follow-up of 1-3 yr, tumor control was seen in all cases. In 4 cases, the tumor 
disappeared. Shrinkage of the tumor was seen in 7 cases and maintained in 6 cases for 6-12 
months. In the remaining 4 cases, tumor size remained stable for 1 year. 
9.1 Methods 
The treatment consisted of surgery and postoperative brachytherapy. For brain stem MG, 
the occipital squama and posterior arch of the atlas were removed. In spinal cord MG, 
laminectomy was performed for decompression in the two adjacent normal vertebral plates. 
Biopsies were conducted as needed. The intra-tumoral sack of the reservoir (Li Anmin I 
reservoir) was implanted near the tumor (Fig. 18). After 7 d, liquid 30 mCi 125I/131I was 
injected via the reservoir valve into the intra-tumoral sack. Radioactive isotope was 
administered every four months (2 half lives of 125I) or 16-21 days (2-3 half lives of 131I) for 
four doses in one cycle. Most of the 15 patients received three treatment cycles. Two patients 
with brain stem MG received two 30 mCi 131I treatments. MRI examination was performed 
at 4 months after therapy.  
 
 
Fig. 18. The sketch of peritumoral brachytherapy for brain stem/spinal cord glioma 
9.2 Efficacy 
Brachytherapy has the advantages of localized high-absorption, long treatment cycles, and 
low radioactive injury to normal neural tissue, and therefore is suitable for patients with MG 
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the brain stem or spinal cord [12,13]. The 15 patients receiving this therapy exhibited 
improved short-term and long-term survival. Two patients survived for >3 years. Post-
treatment MRI revealed that all primary tumors were under control or in partial remission 
(Figs. 19 and 20).  
Typical case: 
 
 
Fig. 19. Female, 11 years old, medulloblastoma 
Treatment: peritumoral Brachytherapy for brain stem glioma  
 
 
Fig. 20. Male, 46 years old, anaplastic astrocytoma in the cervical cord  
Treatment: peritumoral brachytherapy for spinal cord glioma 
9.3 Clinical application of new regional tumor therapy 
Traditional treatments ignore the fact that MG is a localized tumor and target the entire 
body or the entire brain. Such treatments impair the immune and hemotopoeitic  systems, 
and drastically reduce the quality of life. Based on pathogenesis, proliferation, pathological 
types, recurrence mode, and age at onset, MG is classified into six categories: primary 
glioma, recurrent glioma, cystic glioma, glioma in functional zones, low-grade glioma, and 
brain stem/spinal cord glioma.  
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With the goal of improving the quality of life for MG patients, the authors developed seven 
new regional therapeutic methods. Long-term therapeutic plan was individualized for each 
patient.  
Intra-tumoral brachytherapy and selective/super-selective interventional chemotherapy 
were commonly used in combination in our practice. A second common treatment 
combination included brachytherapy, intra-tumor interstitial chemotherapy, and 
selective/super-selective interventional chemotherapy via cerebral artery. (Table 2). 
 
 
 
 
primary 
glioma 
recurrent 
glioma 
cystic 
glioma
glioma in 
functional 
zones 
low-
grade 
glioma 
Brainstem
/-spinal 
cord 
glioma 
Intra-tumoral interstitial 
chemotherapy 
⊙ ⊙ ⊙  ⊙  
Selective/super-selective 
interventional chemotherapy 
via cerebral artery 
⊙ ⊙ ⊙ ⊙ ⊙  
Autologous peripheral blood 
bone marrow stem cell 
supported high-dose 
chemotherapy 
⊙ ⊙     
Intratumoral brachytherapy ⊙ ⊙ ⊙  ⊙  
Immunologically targeted 
radiotherapy via 131I loaded 
McAb 
 ⊙     
Intratumoral interstitial 
brachytherapy 
   ⊙   
Peritumoral brachytherapy for 
brain stem/spinal cord glioma
     ⊙ 
 
 
Table 2. Clinical treatments of the six MG categories. 
The overall 1-year, 2-year, and 3-year survival rate in our patients was 65.0%, 47%, and 
16.6%, respectively. The tumor completely disappeared in 6.3% of the patients. This 
outcome is significantly better than previously reported (Table 3). 
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 country Time cases Therapeutic regimen 
1-year 
survival 
rate 
(%) 
2-year 
survival 
rate 
(%) 
3-year 
survival 
rate  
(%) 
Bloom UK 1966 141 Surgery + Radiotherapy 27 15 8 
Fine USA 1993 3000 
Surgery + 
Radio/chemotherapy 
53.2 25.0 - 
Scott USA 1995 747 
Surgery + 
Radio/chemotherapy 
30 8 2.5 
Davis USA 1999 146 Surgery + Radiotherapy 46 9.0 3.0 
Laws USA 2004 565 
Surgery + 
Radio/chemotherapy 
- 34.5 - 
Li 
Anmin 
CHN 2008 379 Local Therapy 65 47 16.6 
Note: Above data were from following articles: 
Table 3. Clinical outcome of glioma treatments. 
[1] Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation 
therapy with and without adjuvant chemotherapy for malignant gliomas in adults. 
Cancer. 1993, 71(8):2585-97. 
[2] Scott CB, Nelson JS, Farnan NC, Curran WJ Jr, Murray KJ, Fischbach AJ, Gaspar 
LE,Nelson DF.Central pathology review in clinical trials for patients with 
malignant glioma. A Report of Radiation Therapy Oncology Group 83-02. Cancer. 
1995, 76(2):307-13. 
[3] Chen P, Aldape K, Wiencke JK, Kelsey KT, Miike R, Davis RL, Liu J, Kesler-Diaz 
A,Takahashi M, Wrensch M. Ethnicity delineates different genetic pathways in 
malignant glioma. Cancer Res. 2001, 61(10):3949-54. 
[4] Chang SM, Parney IF, Huang W, Anderson FA Jr, Asher AL, Bernstein M, Lillehei KO, 
Brem H, Berger MS, Laws ER; Glioma Outcomes Project Investigators. Patterns of 
care for adults with newly diagnosed malignant glioma. JAMA. 2005, 293(5):557-
64. 
10. Magnetic targeting chemotherapy against brain gliomas 
One of the major problems in chemotherapy for MG is the lack of permeation of 
chemotherapeutic drugs through the BBB and tumor cell membrane. These difficulties may 
be overcome by novel delivery methods. For example, we developed a magnetic targeting 
drug delivery system between 1995 and 2008 (Fig.21). We conducted a series of experiments 
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to examine the distribution, efficacy, and potential toxicity of this system. Results are 
summarized below. 
 
 
Fig. 21. The sketch of magnetic targeting delivery system 
11. Toxicity of magnetic drugs on liver, kidney, and bone marrow  
11.1 Methods 
Sixty Kunming mice were randomly divided into three groups, and received different drugs 
in the presence or absence of an external magnetic field (Table 4). RBC, WBC, PLT, alamine 
aminotransferase (ALT), and blood urea nitrogen (BUN) were measured prior to and at 1, 7, 
14, 30, and 90 d after the treatment.  
 
Groups Drug External Magnetic Field 
Magnetic targeting magnetic MTX drug 0.5T, across head 
MTX MTX Without 
Control saline Without 
Table 4. Toxicity profile. 
11.2 Results 
RBC, WBC, and PLT counts in the MTX group decreased significantly after the treatment, 
reached the lowest levels at 14 d post-injection and recovered after 90 d. In the magnetic 
targeting group, the RBC count was lowest at 7 d post-injection and gradually recovered 
after 90 d.  
Remarkable difference was found among three groups, as shown in Fig. 22, demonstrating 
that magnetic targeting can reduce the toxicity of chemical drugs on bone marrow. Changes 
in ALT and BUN levels reflected the hepatic and renal injury. The magnetic targeting group 
had markedly lower ALT and BUN levels compared to the MTX group, indicating that 
magnetic targeting can reduce the side effects of chemotherapeutic drugs and protect the 
liver, kidneys, and bone marrow from systemic chemotherapy [14]. 
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Fig. 22. Peripheral levels of RBC, WBC, PLT, ALT and BUN at pre-injection, and 1, 7, 14, 30 
and 90 d after drug injection.  
12. Distribution of the magnetic drugs in the brain 
We investigated the distribution of magnetic drugs in the brain under magnetic drug 
targeting and explored magnetic targeting chemotherapy for malignant brain tumors. 
12.1 Methods 
Ninety SD rats were divided into three groups, and received different drugs in the presence 
or absence of an external magnetic field (Table 5). Ten rats from each group were randomly 
selected for sacrifice at 15 min intervals after drug injections. MTX levels in both sides of 
brain of each rat were measured. 
 
Groups Drug External Magnetic Field 
Magnetic targeting magnetic MTX drug 0.5T, across head 
Non-magnetic targeting magnetic MTX drug without 
Control MTX 0.5T , across head 
Table 5. Distribution of magnetic drugs in the brain. 
www.intechopen.com
Regional Chemotherapy and Brachytherapy  
for Malignant Glioma – Clinical Experience and a Serial Experiments 
 
259 
12.2 Results 
MTX concentration in the brain was significantly higher in the magnetic targeting group. 
The difference between the three groups increased with time after injection.    
 
Group 
Drug content in hemispheres post-injection 
15 min 30 min 45 min 
Magnetic targeting 0.28±0.03 a 0.38±0.04 a 0.56±0.02 a 
Non-magnetic targeting  0.10±0.02 0.14±0.01 0.06±0.02 
MTX 0.13±0.12 0.11±0.02 0.07±0.05 
Note: a: P<0.01 vs. other groups 
Table 6. MTX concentration in the brain hemispheres. 
12.3 Conclusions 
Under magnetic targeting, magnetic drugs accumulated in the targeted area in the brain and 
local drug concentrations increased by 2- 9 folds. 
13. Drug delivery by Superparamagnetic Paclitaxel Nanoparticles (SPPNPs) 
13.1 Preparation and characteristics of SPPNPs  
13.1.1 Methods 
SPPNPs were synthesized with octadecyl-quaternized carboxymethyl chitosans and Fe3O4 
ferrofluid, cholesterol, and paclitaxel at a weight ratio of 4:3:3:2 by reverse-phase 
evaporation. The diameters, magnetism, and drug release rates of the SPPNPs were 
examined with transmission electron microscope (TEM), a vibrating sample magnetometer 
(VSM), and high performance liquid chromatography (HPLC).  
13.1.2 Results 
TEM revealed an average diameter of ~20 nm with a narrow size distribution. The VSM 
analysis indicated that the paclitaxel nanoparticles were superparamagnetic (Fig. 23). The 
drug release test showed sustained drug release for >15 days (Fig. 24). 
13.2 Cellular study 
13.2.1 Methods 
We examined intracellular distribution of FITC-labeled SPPNPs in MG cell line C6 under a 
fluorescent microscope. Cytotoxicity and apoptosis-inducing capacity of SPPNPs were also 
examined using CCK-8 kit and flow cytometry, respectively. 
13.2.2 Results 
The nanoparticles were taken up by the glioma cells. Confocal microscopy showed that 
these nanoparticles are present in the cytoplasm. C6 Cells were incubated with magnetic 
paclitaxel nanoparticles containing 1-80 nM paclitaxel or free paclitaxel of the same 
concentrations for 6-24 h. Both free placlitaxel and magnetic paclitaxel nanoparticles 
inhibited the proliferation of C6 cells in a dose and time-dependent manner. Cytotoxicity 
was comparable between free paclitaxel and paclitaxel released from the magnetic 
nanoparticles (Fig. 25).  
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(Magnetic paclitaxel nanoparticles inhibit glioma growth and improve the survival of rats bearing 
glioma xenografts. Anticancer Research, 2010; 30(6): 2217-2223.) 
Fig. 23. The aqueous solution of the magnetic paclitaxel nanoparticles at a concentration of 1 
mg/ml (A) and 0.02 mg/ml (B) (calculated by the paclitaxel content). The same 
concentration of free paclitaxel (1 mg/ml) was insoluble in water (C). Under transmission 
electronic microscope, the magnetic paclitaxel nanoparticles showed a uniform size of 20 nm 
in diameter (D). After an external magnet was placed, the nanoparticles were attracted to the 
container wall (E). Vibrating sample magnetometry showed that these nanoparticles were 
superparamagnetic (F). 
 
 
Fig. 24. In vitro paclitaxel release of free paclitaxel and the magnetic paclitaxel nanoparticles 
(pH 7.4 at 37°C). The results are shown as mean ± S.D.. The experiments were conducted 
three times independently. (Magnetic paclitaxel nanoparticles inhibit glioma growth and improve 
the survival of rats bearing glioma xenografts. Anticancer Research, 2010; 30(6): 2217-2223.) 
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Fig. 25. The in vitro cytotoxicity of the magnetic paclitaxel nanoparticles and free paclitaxel 
against C6 cells at 6h (A), 12h (B) and 24h (C) post drug treatment. The cytotoxicity was 
determined by CCK-8 assays. The results are shown as mean ± S.D.. The experiments were 
conducted three times independently. * indicates P < 0.05. (Magnetic paclitaxel nanoparticles 
inhibit glioma growth and improve the survival of rats bearing glioma xenografts. Anticancer 
Research, 2010; 30(6): 2217-2223.) 
13.3 Animal experiments  
13.3.1 Drug concentration in rat brains after magnetic targeting 
Male Wistar rats were randomly assigned into three groups, and received SPPNPs or PTX in 
the presence or absence of an external magnetic field (Table 7).  
 
Groups Drug External Magnetic Field 
Magnetic targeting SPPNP (2.5 mL/kg) 0.5T, across head 
Non-magnetic targeting SPPNP (2.5 mL/kg) without 
Control PTX  (1.0 mg/mL) without 
Table 7. Treatment conditions in rat experiments. 
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The brain tissues were harvested at 1, 4, 8, and 16 h post-injection. PTX concentration was 
measured by HPLC. 
13.3.1.1 Results 
After intravenous injection of SPPNP, the PTX concentration in the non-magnetic targeting 
group was significantly lower compared to the magnetic targeting group, but markedly 
higher than that in control group (Fig. 26). 
13.3.2 Inhibition of glioma cells in tumor-bearing rats after SPPNP injection and 
magnetic targeting 
13.3.2.1 Methods 
C6 cells were implanted into the rat brain stereotactically. After emergence of brain tumor 
symptoms, rats were divided into three groups. They were treated as shown in the 
following Table 7. 
13.3.2.2 Results 
The effect of free paclitaxel or the SPPNPs on the survival of rats bearing C6 glioma was 
depicted in Fig. 5. We found that the rats that received free paclitaxel at 10 mg/kg had a 
median survival of 12 d and a mean survival of 13.6 d (Tab. 2). The rats that received the 
magnetic paclitaxel nanoparticles and magnetic targeting had a median survival of 27 d and 
a mean survival of 27.4 d with the longest survival at 34 d, whose survival time increased 
for 1.5 times compared to those who received free paclitaxel (Fig. 27). 
 
 
 
 
 
 
 
 
 
 
Fig. 26. Drug Concentration in Rat Brain in 3 Groups. 
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Fig. 27. Kaplan-Meier survival plots for C6 glioma-bearing rats given magnetic paclitaxel 
nanoparticles or free paclitaxel with or without magnetic targeting. MTG: magnetic 
targeting group, injection of magnetic paclitaxel nanoparticles combined with 0.5T magnetic 
field across the head; PTX: commercial paclitaxel was administered. Significantly prolonged 
survival was found in the MTG. (Magnetic paclitaxel nanoparticles inhibit glioma growth and 
improve the survival of rats bearing glioma xenografts. Anticancer Research, 2010; 30(6): 2217-
2223.) 
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14. Conclusion 
SPPNPs are safe and stable vectors to release chemotherapeutic drugs [15]. The small size 
allows SPPNPs to enter tumor cells. In the presence of an external magnetic field, SPPNPs 
can accumulate in magnetic targeted area [16,17]. This treatment inhibited tumor growth and 
prolonged the survival of glioma-bearing rats. 
14.1 Possible mechanisms of magnetic targeting therapy against MG 
1. Increase localized drug concentration 
In the presence of an external magnetic field, magnetic chemotherapeutic drugs move 
within capillaries in the targeted areas of the brain and tumor. This increases the local drug 
concentration dramatically both around the tumor region and in the blood vessels of 
magnetic field [18]. Our results showed that magnetic targeting could increase the local drug 
concentration by 2-15 folds.  
2. Slow release of loaded drugs 
In the magnetic targeted area, the biodegradable capsule of magnetic drugs constantly 
degrades, slowly releasing the drugs into the vasculature or interstitial space of tumors or 
inside the tumor cells. This slow-release produces a sustained inhibition of the tumor cells. 
3. Thrombosis by magnetic particles  
Neoplastic deformation of tumor vasculature and ferrofluid in the magnetic field may 
facilitate the formation of micro-thrombi in the tumor capillary vessel and microvessel, and 
decrease the blood supply to the tumor [19]. 
4. Improve the penetration across biological membrane 
The penetration of drugs across BBB depends on the local concentration gradient across the 
brain endotheliocytes. Magnetic targeting increases the drug content in the interstitial fluid 
of tumor. In addition to this concentration gradient, the strong magnetic field promotes the 
movement of the magnetic drug into the tumor from the capillary vessels and microvessels. 
Permeability and endocytosis permit the magnetic particles and chemotherapeutic drugs to 
enter the tumor cells [20]. 
5. Magnetic-chemotherapeutic effects of magnetic particles 
The magnetic particles and external magnetic field may have synergistic action. In 
traditional Chinese medicine, magnetite has been used to generate magnetic field in tumor 
patients. In magnetic targeting therapy, the encapsulated ferrofluid can generate the 
magnetic-chemotherapeutic antineoplastic effects [21]. 
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